following an abbreviated submission:
mirikizumab (Omvoh®) is accepted for use within NHSScotland.
Indication under review: For the treatment of adult patients with moderately to severely active ulcerative colitis who have had an inadequate response with, lost response to, or were intolerant to either conventional therapy or a biologic treatment.
Mirikizumab offers an additional treatment choice in the therapeutic class of interleukin inhibitors.
This advice applies only in the context of approved NHSScotland Patient Access Scheme (PAS) arrangements delivering the cost-effectiveness results upon which the decision was based, or PAS/ list prices that are equivalent or lower.
Download detailed advice274KB (PDF)
Medicine details
- Medicine name:
- mirikizumab (Omvoh)
- SMC ID:
- SMC2650
- Indication:
For treatment of adults with moderately to severely active ulcerative colitis who are intolerant of, or whose disease has had an inadequate response or loss of response to, either conventional therapy or a biologic or have medical contraindications to such therapies.
- Pharmaceutical company
- Eli Lilly and Company Ltd
- BNF chapter
- Gastro-intestinal system
- Submission type
- Abbreviated
- Status
- Accepted
- Date advice published
- 08 April 2024